Chemotherapy-and cancer-related nausea and vomiting

Current Oncology

Volumn 15, Issue S1, 2008, Pages S4-S9

  Warr, D G ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

5 hydroxy tryptamine3; aprepitant; chemotherapy; emesis; Nausea; neurokinin; vomiting

Indexed keywords

EID: 49649095563     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2008.171     Document Type: Article

References (30)

1. 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005;41:1278–85.
2. Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time … nothing was working.” JAMA 2007;298:1196–207.
3. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 2006;129:3–16.
4. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003; 97:2880–6.
5. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer 2006;14: 348–53.
6. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treat-ment of nausea in patients with far-advanced cancer. Support Care Cancer 2004;12:432–40.
7. Laval G, Girardier J, Lassauniere JM, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med 2000;14:3–10.
8. Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res 2002;22:1187–92.
9. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treat-ing and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 1999;17:344–51.
10. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerabil-ity of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23: 2822–30.
11. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301–8.
12. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with can-cer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 1996;14:2242–9.
13. Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol 2005;1:143–9.
14. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–7.
15. 3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473–82.
16. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441–9.
17. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncol-ogy: update 2006. J Clin Oncol 2006;24:2932–47.
18. 1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249:R3–4.
19. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neuroki-nin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112–19.
20. Poli–Bigelli S, Rodrigues–Pereira J, Carides AD, et al. Addi-tion of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090–8.
21. Schmoll HJ, Aapro MS, Poli–Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regi-men, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000–6.
22. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:609–16.
23. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacoki-netics in cancer patients. Cancer Chemother Pharmacol 2007; 59:407–12.
24. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharma-cokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17–24.
25. Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341–6.
26. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20–8.
27. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxy-tryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765–72.
28. Srivastava M, Brito–Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003;25: 578–82.
29. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529–34.
30. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007;15: 1285–91.